GC Genome Corporation (KOSDAQ:340450)

Total Valuation

GC Genome has a market cap or net worth of KRW 170.29 billion. The enterprise value is 126.89 billion.

Market Cap	170.29B
Enterprise Value	126.89B

Important Dates

Earnings Date	n/a
Ex-Dividend Date	n/a

Share Statistics

GC Genome has 23.65 million shares outstanding. The number of shares has increased by 19.30% in one year.

Current Share Class	23.65M
Shares Outstanding	23.65M
Shares Change (YoY)	+19.30%
Shares Change (QoQ)	+4.76%
Owned by Insiders (%)	15.52%
Owned by Institutions (%)	n/a
Float	10.20M

Valuation Ratios

The trailing PE ratio is 12,930.14.

PE Ratio	12,930.14
Forward PE	n/a
PS Ratio	5.93
PB Ratio	2.31
P/TBV Ratio	2.33
P/FCF Ratio	505.64
P/OCF Ratio	301.32
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 37.31, with an EV/FCF ratio of 376.78.

EV / Earnings	9,634.84
EV / Sales	4.42
EV / EBITDA	37.31
EV / EBIT	n/a
EV / FCF	376.78

Financial Position

The company has a current ratio of 10.22, with a Debt / Equity ratio of 0.06.

Current Ratio	10.22
Quick Ratio	9.82
Debt / Equity	0.06
Debt / EBITDA	1.29
Debt / FCF	13.04
Interest Coverage	0.63

Financial Efficiency

Return on Equity (ROE)	n/a
Return on Assets (ROA)	n/a
Return on Invested Capital (ROIC)	n/a
Return on Capital Employed (ROCE)	0.44%
Revenue Per Employee	n/a
Profits Per Employee	n/a
Employee Count	n/a
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	-4.15M
Effective Tax Rate	n/a

Stock Price Statistics

Beta (5Y)	n/a
52-Week Price Change	n/a
50-Day Moving Average	7,902.80
200-Day Moving Average	n/a
Relative Strength Index (RSI)	33.52
Average Volume (20 Days)	91,440

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, GC Genome had revenue of KRW 28.70 billion and earned 13.17 million in profits. Earnings per share was 0.68.

Revenue	28.70B
Gross Profit	12.96B
Operating Income	343.67M
Pretax Income	9.02M
Net Income	13.17M
EBITDA	3.40B
EBIT	343.67M
Earnings Per Share (EPS)	0.68

Balance Sheet

The company has 47.79 billion in cash and 4.39 billion in debt, giving a net cash position of 43.40 billion or 1,834.95 per share.

Cash & Cash Equivalents	47.79B
Total Debt	4.39B
Net Cash	43.40B
Net Cash Per Share	1,834.95
Equity (Book Value)	73.74B
Book Value Per Share	3,117.90
Working Capital	52.43B

Cash Flow

In the last 12 months, operating cash flow was 565.12 million and capital expenditures -228.35 million, giving a free cash flow of 336.77 million.

Operating Cash Flow	565.12M
Capital Expenditures	-228.35M
Free Cash Flow	336.77M
FCF Per Share	14.24

Margins

Gross margin is 45.16%, with operating and profit margins of 1.20% and 0.05%.

Gross Margin	45.16%
Operating Margin	1.20%
Pretax Margin	0.03%
Profit Margin	0.05%
EBITDA Margin	11.85%
EBIT Margin	1.20%
FCF Margin	1.17%

Dividends & Yields

GC Genome does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-19.30%
Shareholder Yield	n/a
Earnings Yield	0.01%
FCF Yield	0.20%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

GC Genome has an Altman Z-Score of 15.09 and a Piotroski F-Score of 5.

Altman Z-Score	15.09
Piotroski F-Score	5